Article Impact Level: HIGH Data Quality: STRONG Summary of New England Journal of Medicine https://doi.org/10.1056/NEJMoa2506295 Dr. Linda Laux et al.
Points
- Researchers surveyed over five hundred adults to determine the minimum heart disease risk reduction they would require to justify taking a daily statin medication for primary prevention purposes.
- The study found that nearly forty-three percent of participants would decline statins at a ten percent risk level because they expected much higher benefits than the drugs provide.
- Most participants required an absolute risk reduction of at least seven point five percentage points which represents a much larger effect size than the typical twenty-five percent relative reduction.
- Refusal rates were highest among low-risk individuals with over sixty percent declining treatment even if the drug could theoretically lower their cardiovascular risk down to zero percent entirely.
- Integrating the smallest worthwhile difference metric into clinical practice could help doctors better align their medical recommendations with patient preferences to improve long-term adherence to heart medications.
Summary
Heart disease remains a leading cause of death, and while statins effectively reduce LDL cholesterol, patient adherence is limited by a discrepancy between clinical benefits and personal expectations. A study of 551 adults in the U.S. and Japan utilized the smallest worthwhile difference (SWD) metric to quantify the minimum risk reduction required for patients to initiate therapy. While current guidelines recommend treatment at a 7.5% 10-year risk level, the study found that 42.9% of U.S. and 42.4% of Japanese participants at a 10% baseline risk declined medication, often demanding a 50-75% risk reduction (an absolute reduction of 7.5 percentage points) before considering treatment worthwhile.
The researchers analyzed how these preferences shifted across risk tiers. At a low 2% baseline risk, refusal rates reached 75.6% in the U.S. and 62.3% in Japan, even if the medication could theoretically reduce risk to zero. However, as baseline risk increased to 20%, refusal rates dropped to 23.6% in the U.S. and 38.4% in Japan. These findings highlight that patients are more willing to accept smaller relative benefits when their absolute risk is higher, yet their general expectations still far exceed the 25% relative risk reduction typically delivered by standard statin therapy in clinical practice.
The data suggest that expert-derived guidelines lack sufficient patient input, creating a gap between medical necessity and patient desire. By utilizing the SWD framework, clinicians can better facilitate shared decision-making and align treatment plans with the values of their patients. Addressing this gap is essential for improving long-term adherence to primary prevention strategies for cardiovascular disease and stroke. The researchers advocate for incorporating patient-centered metrics into future guidelines to ensure that recommendations are both medically sound and personally acceptable to the target population.
Link to the article: https://www.nejm.org/doi/10.1056/NEJMoa2506295
References
Laux, L., Sullivan, J., Perry, M. S., Brunklaus, A., Desurkar, A., Schreiber, J. M., Roberts, C. M., Knupp, K. G., Wheless, J. W., Wirrell, E. C., Ventola, P., Wang, F., Meena, Lynch, J., Parkerson, K. A., Ticho, B., & Cross, J. H. (2026). Zorevunersen in children and adolescents with dravet syndrome. New England Journal of Medicine, 394(10), 969–982. https://doi.org/10.1056/NEJMoa2506295
